Last reviewed · How we verify
PLX038
At a glance
| Generic name | PLX038 |
|---|---|
| Also known as | PEGylated SN38 |
| Sponsor | ProLynx LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (PHASE1, PHASE2)
- PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (PHASE2)
- A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (PHASE1)
- A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (PHASE2)
- PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers (PHASE1, PHASE2)
- A Phase I Study of PLX038 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLX038 CI brief — competitive landscape report
- PLX038 updates RSS · CI watch RSS
- ProLynx LLC portfolio CI